PMID- 36206015 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20230104 IS - 1557-7732 (Electronic) IS - 1080-7683 (Linking) VI - 38 IP - 10 DP - 2022 Dec TI - Characteristics and Potential Risk Factors of Hydroxychloroquine Retinopathy in Patients with Systemic Lupus Erythematosus: Focusing on Asian Population. PG - 728-733 LID - 10.1089/jop.2022.0060 [doi] AB - Purpose: Hydroxychloroquine (HCQ) would cause irreversible retinal damage, despite its pivotal role in treatment of systemic lupus erythematosus (SLE). This study aims to reassess the characteristics and risk factors of HCQ retinopathy. Methods: This study included patients with SLE who had used HCQ for >5 years and received ophthalmologic examinations during November 2017 to December 2020 in a tertiary hospital in Taiwan. Spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) were performed in all patients. Visual field assessment and/or multifocal electroretinography were done if suspicious findings were noted by SD-OCT or FAF. Clinical features and dosing details of HCQ were recorded by chart review. Results: Ninety-two patients were included, with the median duration of drug exposure of 11.2 years [interquartile range (IQR) 9.4-12.7 years], median daily dose of 6.9 mg/kg (IQR 6.1-7.7 mg/kg), and cumulative dose of 1,503.6 g (IQR 1,257.7-1,805.9 g). HCQ retinopathy was diagnosed in 10.9% of patients (10 of 92), and in 20.8% of patients (5 of 24) who complained about blurred vision. High myopia [odds ratio (OR) 5.03; 95% confidence interval (CI) 1.29-24.79; P = 0.03] and lower body weight (OR 0.88; 95% CI 0.78-0.97; P = 0.03) were significantly associated with HCQ retinopathy. Conclusions: Long-term HCQ users may suffer from retinal toxicity. Since there is no optimal substitute for HCQ, careful retinal evaluation is needed to avoid unnecessary drug discontinuation. In addition, an association between high myopia and HCQ retinopathy was noted. More investigation is needed to clarify this association. FAU - Kao, Jui-Hung AU - Kao JH AUID- ORCID: 0000-0002-8236-9121 AD - Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin County, Taiwan. FAU - Lai, Tso-Ting AU - Lai TT AD - Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan. AD - Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. FAU - Lu, Cheng-Hsun AU - Lu CH AD - Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. FAU - Lan, Ting-Yuan AU - Lan TY AD - Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu County, Taiwan. FAU - Hsieh, Yi-Ting AU - Hsieh YT AD - Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan. FAU - Shen, Chieh-Yu AU - Shen CY AD - Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. AD - Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. FAU - Li, Ko-Jen AU - Li KJ AD - Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. FAU - Hsieh, Song-Chou AU - Hsieh SC AD - Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. LA - eng PT - Journal Article DEP - 20221007 PL - United States TA - J Ocul Pharmacol Ther JT - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics JID - 9511091 SB - IM MH - Humans MH - *Lupus Erythematosus, Systemic/complications/drug therapy MH - Risk Factors OTO - NOTNLM OT - hydroxychloroquine OT - myopia OT - retinopathy OT - risk factor OT - systemic lupus erythematosus EDAT- 2022/10/08 06:00 MHDA- 2022/12/15 06:00 CRDT- 2022/10/07 11:42 PHST- 2022/10/08 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/10/07 11:42 [entrez] AID - 10.1089/jop.2022.0060 [doi] PST - ppublish SO - J Ocul Pharmacol Ther. 2022 Dec;38(10):728-733. doi: 10.1089/jop.2022.0060. Epub 2022 Oct 7.